Current Report Filing (8-k)
March 08 2021 - 5:28PM
Edgar (US Regulatory)
false 0001175680 0001175680 2021-03-08 2021-03-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 8, 2021
CytoDyn Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49908
|
|
83-1887078
|
(State or other jurisdiction
of incorporation)
|
|
(SEC
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1111 Main Street, Suite 660
Vancouver, Washington 98660
(Address of principal executive offices)
(360) 980-8524
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
None.
|
|
None.
|
|
None.
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure
|
Attached as Exhibit 99.1 is a copy of CytoDyn Inc.’s Executive Summary of the data from its Phase 2b/3, two-arm, randomized, double-blind, placebo-controlled trial to evaluate its investigational drug leronlimab’s safety and efficacy as add-on therapy in patients being treated with institutional standard of care for severe-to-critical COVID-19 patients.
The information in this Current Report on Form 8-K and in Exhibit 99.1 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CytoDyn Inc.
|
|
|
|
|
Dated: March 8, 2021
|
|
|
|
By:
|
|
/s/ Michael D. Mulholland
|
|
|
|
|
|
|
Michael D. Mulholland
Chief Financial Officer
|
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Sep 2023 to Sep 2024